Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ramipril · 3 trials · 4 indications
Sotagliflozin with ramipril: Area under the curve (AUC) to the end of the dosing period (AUCtau)
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Ramipril |
| 2 | NO_INTERVENTION | - |
| SAR439954 with or without ramipril | EXPERIMENTAL | * On Period 1, following an overnight fast, subjects will receive once daily single morning oral intake of sotagliflozin from Day 1 to Day 5 followed by the first meal that has to be started within 10 min after dosing. * On Day 1 of the Period 2, study subjects will begin a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing. |
| Name | Type | Description |
|---|---|---|
| Ramipril | DRUG | 2.5mg and increase to 5mg if patient do not develop symptomatic hypotension |
| Sotagliflozin (SAR439954) | DRUG | Pharmaceutical form: tablets Route of administration: oral |
Inclusion Criteria: * biopsy-confirmed IgA nephropathy * proteinuria less than 0.5 g per day, normal blood pressure, and serum creatinine below 120 µmol/l Exclusion Criteria: * pregnant or nursing mother, or women of childbearing potential without an effective method of birth control * history of...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | APLS | 2 | PHASE3 | Pegcetacoplan |
Ramipril is a small molecule ACE inhibitor developed by Sanofi. It is being studied in diabetes mellitus, glomerulonephritis, and myocardial ischemia. Ramipril is an investigational therapy in clinical development rather than a newly approved product, and it has been evaluated in completed Phase 1 and Phase 3 trials.
Ramipril targets ACE, or angiotensin-converting enzyme, and acts as an inhibitor of that target. By inhibiting ACE, Ramipril belongs to the ACE inhibitor class of small molecule agents. This mechanism underlies its evaluation across metabolic and cardiovascular indications including diabetes mellitus, glomerulonephritis, and myocardial ischemia.
Ramipril is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor associated with the clinical development program for Ramipril across its studied indications, including diabetes mellitus, glomerulonephritis, and myocardial ischemia.
Ramipril has been studied in Phase 1 and Phase 3 clinical trials, all of which are completed. It is an investigational agent in clinical development. The program includes one Phase 1 drug-drug interaction study and two Phase 3 studies, with no active trials currently listed.
Ramipril has been evaluated in completed trials including NCT03414723, a Phase 1 drug-drug interaction study with sotagliflozin in diabetes mellitus and healthy subjects in Germany; NCT00437463, a Phase 3 study in IgA nephropathy and glomerulonephritis in Hong Kong; and NCT00268619, the Phase 3 FOCUS study in myocardial ischemia.